{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-034120","form_type":"8-K/A","ticker":"OSRH","cik":"0001840425","company_name":"OSR Holdings, Inc.","filed_at":"2025-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.065893+00:00","generated_at":"2026-05-23T09:29:41.632880+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OSR Holdings files audited FY2024 financials for Legacy OSR; net loss widens to ₩14.1B","bullets":["Net loss of ₩14.09B (₩7,466 per share) for 2024 vs ₩13.61B loss in 2023 on revenue of ₩4.82B (+8% YoY).","Operating loss increased to ₩15.95B from ₩14.78B; SG&A expenses grew to ₩17.05B.","Total assets ₩257.6B, equity ₩210.5B; cash and equivalents dropped to ₩502M from ₩697M.","Key subsidiaries: VAXIMM (Switzerland, biotech), RMC (medical devices, Korea), Darnatein (biotech, Korea)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-034120","json":"https://secwatch.observer/filing/0001213900-25-034120.json","markdown":"https://secwatch.observer/filing/0001213900-25-034120.md","text":"https://secwatch.observer/filing/0001213900-25-034120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840425/000121390025034120/0001213900-25-034120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840425/000121390025034120/ea0238120-8ka1_osr.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T09:29:41.632880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}